BioXcel Therapeutics, Inc. (BTAI)
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Investigation
02/22/2021
Initial Lawsuit
04/18/2021
Lawsuit Progression
09/16/2021
Investigation regarding misleading statements made in connection with Chuchill’s Capital Corp. IV’s merger with Lucid Motors.
02/22/2021
Journalist Ed Ludlow from Bloomberg News reports that Lucid’s CEO Peter Rawlinson said during an interview, that as a result of Churchill’s diligence process, Lucid would not honor its previous statements about “spring production” and had decided to delay production but would not commit to any specific date.
See more on Factual TimelineThis is a federal securities class action on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Churchill Capital Corp IV securities between January 11, 2021 and February 22, 2021, both dates inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) employed devices, schemes, and artifices to defraud;
(ii) made untrue statements of material fact and/or omitted to state material facts necessary to make the statements not misleading;
(iii) engaged in acts, practices, and a course of business which operated as a fraud and deceit upon those who purchased or otherwise acquired CCIV’s securities during the class period.
09/16/2021
The court issued an order appointing the lead plaintiff and lead counsel.
12/16/2021
Plaintiffs bring this federal securities class action on behalf of themselves and all persons or entities who purchased "CCIV Securities" from February 5, 2021, through February 22, 2021, inclusive. The term "CCIV" refers to Lucid Group, Inc. formerly known as Churchill Capital Corp IV. The term “CCIV Securities” refers to all of CCIV common stock, CCIV Units, CCIV warrants, and call options tied to CCIV common stock, and all of the CCIV Securities were economically tied to the value and price of Lucid common stock.
Additional amended complaints have been filed, please refer to the last filed amended complaint for up-to-date information.
12/30/2021
Plaintiffs bring this federal securities class action pursuant to Rule 23 of the Federal Rules of Civil Procedure on behalf of themselves and all persons and entities that purchased CCIV Securities from February 5, 2021, through February 22, 2021 inclusive (the class period) and were damaged by the conduct alleged herein (the class). CCIV Securities, which are defined at Paragraph 41 of the revised amended complaint, include CCIV common stock (ticker: “CCIV”), CCIV Units (ticker: “CCIVU”), CCIV warrants (ticker: “CCIVW”), and call options for CCIV common stock.
Operative complaint
02/14/2022
A motion to dismiss was filed with the court.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.